Global Recombinant Human Thrombopoietin (rhTPO) Market Research Report 2020-2029 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Recombinant Human Thrombopoietin (rhTPO) Market


Thrombopoietin (TPO), the major physiological regulator of platelet formation, binds to and activates TPO receptor on megakaryocytes, thereby promoting platelet production. Recombinant human thrombopoietin (rhTPO) is a novel therapeutic option for patients with immune thrombocytopenia (ITP) in China. In 2020, the market size of Recombinant Human Thrombopoietin (rhTPO) is xx million US$ and it will reach xx million US$ in 2026, growing at a CAGR of xx% from 2021; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2026, with a CAGR of xx% during forecast period. In this report, 2020 has been considered as the base year and 2021 to 2026 as the forecast period to estimate the market size for Recombinant Human Thrombopoietin (rhTPO). This report studies the global market size of Recombinant Human Thrombopoietin (rhTPO), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Recombinant Human Thrombopoietin (rhTPO) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

Market Segmentation, Outlook & Regional Insights: Recombinant Human Thrombopoietin (rhTPO) Market

Segmentation by Product Type: Breakdown of data from the year 2015 to 2020 and forecast until 2026

 	
rhTPO
 	
Fusion Protein

Segmentation by Application: Breakdown of data from the year 2015 to 2020 and forecast until 2026

 	
Medication
 	
Scientific Research

Key Players, Recent Developments & Sector Viewpoints: Recombinant Human Thrombopoietin (rhTPO) Market

 	
Qilu Pharmaceutical
 	
R&D Systems
 	
Merck
 	
Shionogi
 	
MedChemExpress
 	
PeproTech
 	
Kelun

In Jan 2020, Instituto Grifols S.A. received marketing authorization valid throughout the European Union for Tavlesse which is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked.

Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defenses) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily.

Tavlesse contains the active substance fostamatinib.

Key Insights Covered: Exhaustive Recombinant Human Thrombopoietin (rhTPO) Market
1. Market size (sales, revenue and growth rate) of Recombinant Human Thrombopoietin (rhTPO) industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Recombinant Human Thrombopoietin (rhTPO) industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Recombinant Human Thrombopoietin (rhTPO) industry.
4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Recombinant Human Thrombopoietin (rhTPO) industry.

Research Methodology: Recombinant Human Thrombopoietin (rhTPO) Market

 	
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
 	
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
 	
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.